Kestra Medical Technologies (NASDAQ:KMTS) Stock: Insider Vaseem Mahboob Sells 39,903 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) CFO Vaseem Mahboob sold 39,903 shares of the stock in a transaction that occurred on Wednesday, October 28th. The shares were sold at an average price of $30.48, for a total transaction of $1,216,243.44. Following the completion of the transaction, the chief financial officer owned 60,609 shares in the company, valued at $1,847,362.32. This represents a 39.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Vaseem Mahboob also recently made the following trade(s):

• On Tuesday, October 27th, Vaseem Mahboob sold 34,809 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $30.04, for a total transaction of $1,045,662.36.
• On Thursday, October 29th, Vaseem Mahboob sold 4,788 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $30.60, for a total transaction of $146,512.80.
• On Friday, August 7th, Vaseem Mahboob sold 26,287 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $25.88, for a total transaction of $680,307.56.
• On Tuesday, August 4th, Vaseem Mahboob sold 6,995 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $24.68, for a total transaction of $172,636.60.
• On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $23.80, for a total transaction of $128,305.80.
• On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.61, for a total transaction of $199,352.37.

Kestra Medical Technologies Price Performance

Shares of NASDAQ:KMTS opened at $29.69 on Friday. The company’s fifty day moving average price is $26.69 and its 200 day moving average price is $23.82. Kestra Medical Technologies, Ltd. has a 12 month low of $17.34 and a 12 month high of $31.06. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.69 and a quick ratio of 4.69. The firm has a market capitalization of $1.77 billion, a P/E ratio of -11.12 and a beta of 0.51.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Monday, September 14th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.14). Kestra Medical Technologies had a negative net margin of 140.43% and a negative return on equity of 63.83%. The company had revenue of $30.97 million during the quarter. As a group, sell-side analysts predict that Kestra Medical Technologies, Ltd. will post -2.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Sterling Capital Management LLC boosted its stake in shares of Kestra Medical Technologies by 834.0% during the third quarter. Sterling Capital Management LLC now owns 878 shares of the company’s stock worth $25,000 after buying an additional 784 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in Kestra Medical Technologies in the 3rd quarter valued at about $353,000. Quantinno Capital Management LP acquired a new position in Kestra Medical Technologies in the 1st quarter valued at about $431,000. California State Teachers Retirement System raised its stake in Kestra Medical Technologies by 39.2% during the 1st quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock valued at $555,000 after acquiring an additional 7,844 shares during the last quarter. Finally, Spartan Wealth Advisory Services LLC purchased a new stake in Kestra Medical Technologies during the 1st quarter valued at approximately $603,000.

Key Stories Impacting Kestra Medical Technologies

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Kestra will participate in upcoming investor conferences, which could improve visibility for its wearable cardiac-monitoring and defibrillation platform and give management an opportunity to discuss growth plans. Kestra Medical Technologies to Participate in Upcoming Investor Conferences
• Neutral Sentiment: Analyst sentiment remains generally constructive, with five Buy ratings, two Holds and one Sell rating. Evercore initiated coverage with an Outperform rating and a $34 price target, while the reported average target is $29. However, the company remains unprofitable, and its latest quarterly loss exceeded consensus expectations.
• Negative Sentiment: Insider selling is the clearest near-term negative catalyst. CFO Vaseem Mahboob sold 79,500 shares across October 27–29 for approximately $2.41 million, reducing his direct holdings to 60,609 shares. Director Traci Umberger separately sold 30,000 shares for about $900,900. The transactions may raise concerns about insider confidence or encourage profit-taking after KMTS’s strong advance. Kestra Medical Technologies Insider Selling
• Negative Sentiment: Fundamentals remain a risk: Kestra reported a quarterly loss of $0.75 per share versus the expected $0.61 loss, with a negative net margin and analysts projecting a full-year loss of approximately $2.45 per share.

Wall Street Analysts Forecast Growth

KMTS has been the subject of a number of research analyst reports. Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a research report on Wednesday, July 15th. BTIG Research reaffirmed a “buy” rating and set a $32.00 price target on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Oppenheimer initiated coverage on Kestra Medical Technologies in a research note on Tuesday, July 21st. They issued a “market perform” rating for the company. Weiss Ratings raised Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 16th. Finally, Evercore started coverage on Kestra Medical Technologies in a report on Tuesday, October 20th. They issued an “outperform” rating and a $34.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $29.00.

About Kestra Medical Technologies

Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient’s heart rhythm and deliver a therapeutic shock when clinically necessary.

The company’s platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.